CL
42
-9
SLG
52
4
AAPL
58
2
CTSH
65
2
VRSK
29
-3
NEM
65
-3
LYB
64
2
CINF
43
2
TGNA
56
-2
PEP
60
-2
GT
46
-4
KMB
57
-2
AMZN
52
6
MOS
72
2
PEG
53
-2
XRX
59
-4
PNR
69
15
NOC
32
-3
JCI
63
2
BRK.B
31
-3
CL
42
-9
SLG
52
4
AAPL
58
2
CTSH
65
2
VRSK
29
-3
NEM
65
-3
LYB
64
2
CINF
43
2
TGNA
56
-2
PEP
60
-2
GT
46
-4
KMB
57
-2
AMZN
52
6
MOS
72
2
PEG
53
-2
XRX
59
-4
PNR
69
15
NOC
32
-3
JCI
63
2
BRK.B
31
-3
Financhill
Back

Pliant Therapeutics 10K Form

Buy
100

PLRX
Pliant Therapeutics

Last Price:
34.47
Seasonality Move:
-10.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLRX News And Ratings

See the #1 stock for the next 7 days that we like better than PLRX

PLRX Financial Statistics

Sales & Book Value

Annual Sales: $7.57M
Cash Flow: $-19.19M
Price / Cash Flow: 0
Annual Sales: $6.91
Price / Book: 5.05

Profitability

EPS (TTM): -2.93000
Net Income (TTM): $-112.79M
Gross Margin: --
Return on Equity: -52.31%
Return on Assets: -46.45%

Pliant Therapeutics Earnings Forecast

Key Pliant Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,024.44% of Revenue.
  • The Net Earning history of PLRX is -1,284.81% of Total Revenues.
  • Per Share Earnings over the last 4 years have been positive in 1 years.

Pliant Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: PLRX
CUSIP: 729139
Website: pliantrx.com

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 13.99
Quick Ratio: 13.86

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PLRX Technical Analysis vs Fundamental Analysis

Buy
100
Pliant Therapeutics (PLRX) is a Buy

Is Pliant Therapeutics a Buy or a Sell?